Steritas LLC., a company dedicated to enhancing care for steroid-treated patients, today announced a licensing agreement with argenx, a global immunology company, for use of its STOX® Suite of steroid ...

Discover a trial that included 135 adults, randomly assigned to receive either inebilizumab or a placebo for a 52-week ...

Sivakumar VijayaraghavaluThe formative years of childhood, especially from birth to age five, lay the foundation for lifelong health and well-being. Unfortunately, when young children are subjected to ...

Osteoporosis is a common condition characterized by weak and brittle bones, which makes individuals more prone to fractures.

CNW/ - Thryv Therapeutics Inc., a clinical-stage biotechnology company pioneering novel therapies for cardiovascular diseases ...

3 Centre de Recherche en Epidémiologie et Statistiques (CRESS), Unité Inserm 1153, Université Paris Cité, Paris, France ...

Discover how inebilizumab reduces flares and improves remission rates in IgG4-related disease in this phase 3 clinical trial.

For patients with immunoglobulin G (IgG)4-related disease, inebilizumab reduces the risk for flares and increases the ...